

#11
BP
8-14-01

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:	
8/1/01 Date	 Signature

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Mar Tormo
Ana M. Tari
Gabriel Lopez-Berestein
Timothy J. McDonnell

Group Art Unit: 1635

Examiner: K. Lacourciere

Atty. Dkt. No.: UTSC:550/DLP

Serial No.: 09/381,747

Filed: September 22, 1999

For: INHIBITION OF BCL-2 PROTEIN
EXPRESSION BY LIPOSOMAL
ANTISENSE
OLIGODEOXYNUCLEOTIDES

DISCLAIMING DECLARATION

Hon. Asst. Commissioner
for Patents
Washington, D.C. 20231

We, Ana M. Tari and Gabriel Lopez-Berestein, hereby declare as follows:

1. We, along with Mar Tormo and Timothy J. McDonnell, are the sole joint inventors of all claims currently pending in the referenced patent application.

2. We understand that the Patent and Trademark examiner has found that the publication of Tormo *et al.*, vol. 37 of the *Proceedings of the Eighty-Seventh Annual Meeting of the*
25047450.1

American Association for Cancer Research, March, 1996, is relevant to various of the currently pending claims.


3. We, along with Mar Tormo and Timothy J. McDonnell, are the only joint inventors listed as authors of the Tormo *et al.* article, in that the other individuals named as authors, M. Khodadadlan and F. Cabanillas and J. Garcia-Conde, worked entirely under our direction and control and/or did not contribute to the conception of the invention of the currently pending claims.


4. Mojgan Khodadadlan was a technician who worked entirely under the direction and control of the named inventors, and contributed to the research described in the foregoing abstract by carrying out various western blots under the direction of the inventors. Ms. Khodadadlan did not contribute conceptually to any aspects of the currently pending claims.

5. Fernando Cabanillas was the department head of the lymphoma department at M.D. Anderson Cancer Center whose name was listed as a co-author based only on his contribution of background knowledge regarding lymphomas. Dr. Cabanillas did not contribute conceptually to any aspects of the currently pending claims.

6. Javier Garcia-Conde was the employer of Dr. Tormo prior to her matriculation to M.D. Anderson as a post-doctoral fellow. Dr. Garcia-Conde was listed as a co-author based on his contribution of background knowledge and support. Dr. Garcia-Conde did not contribute conceptually to any aspects of the currently pending claims.

7. We hereby declare that all statements made of our own knowledge are true and all statements made on information are believed to be true and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of this application or any patent issued thereon.



Ana Tari


Gabriel Lopez-Berestein

7/31/01
Date
7/31/01
Date